Seaport Therapeutics and Monash Institute Awarded $15M ARPA-H Grant

Funding will support development of new treatments for rare diseases.

Published on Mar. 3, 2026

Got story updates? Submit your updates here. ›

Seaport Therapeutics, a Boston-based biopharmaceutical company, and the Monash Institute of Pharmaceutical Sciences in Australia have been awarded up to $15 million in funding from the Advanced Research Projects Agency for Health (ARPA-H) to support the development of new treatments for rare diseases.

Why it matters

This grant represents a significant investment in innovative pharmaceutical research and development, with the potential to lead to breakthroughs in treating rare and underserved medical conditions. The collaboration between Seaport Therapeutics and the Monash Institute also highlights the growing global nature of the biopharmaceutical industry.

The details

The ARPA-H grant will enable Seaport Therapeutics and the Monash Institute to accelerate their joint research and development efforts focused on rare disease treatments. The funding will support preclinical studies, clinical trials, and other activities aimed at bringing new drug candidates to market.

  • The grant was awarded on March 3, 2026.

The players

Seaport Therapeutics

A Boston-based biopharmaceutical company focused on developing new treatments for rare diseases.

Monash Institute of Pharmaceutical Sciences

A leading pharmaceutical research institute located in Australia and affiliated with Monash University.

ARPA-H

The Advanced Research Projects Agency for Health, a new U.S. government agency established to support high-risk, high-reward biomedical and health research.

Got photos? Submit your photos here. ›

What’s next

The funding will enable Seaport Therapeutics and the Monash Institute to accelerate their joint research and development efforts, with the goal of advancing new drug candidates into clinical trials.

The takeaway

This grant represents a significant investment in innovative pharmaceutical research and development, with the potential to lead to breakthroughs in treating rare and underserved medical conditions through the collaboration between Seaport Therapeutics and the Monash Institute.